DNA 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围

03
价格 $12.35
市值 (MRQ) $787M
P/E -2.3
EPS $-5.64
收入 $170M
ROE -55.8%
52周区间 $5–$18

DNA 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图

04
区间
条形图

柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。

股票拆分 1
除息日 拆股 类型
2024年8月20日 1-for-40 反向

关于 Ginkgo Bioworks Holdings, Inc. Class A Common Stock 公司概况(来自维基百科)

05 · wikidata

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.

History

In 2014, Ginkgo was the first biotechnology company to join the Y Combinator start-up accelerator program.

On 16 December 2020, it was reported that Ginkgo Bioworks would acquire the primary assets of Novogy's Microbial Engineering Platform. 2020 also saw the company acquire property worth $25 million from Marcus Partners for the construction of a new 219,000 square foot laboratory building, after razing existing structures, located in the Raymond L Flynn Marine Park. As of 2021, the company also occupied 200,000 square feet of the Innovation and Design Building (aka IDB) in the Park. Ginkgo also occupied facilities in Cambridge, where most MIT-spin outs resided at the time.

Growth of Ginkgo up to 2021 had been driven by "robust venture capital funding" and entry into the COVID-19 testing market. This included $45 million from Viking Global in 2015.

On 11 May 2021, Ginkgo Bioworks announced plans of going public through a merger with SPAC Soaring Eagle at a $17.5 billion valuation.

On 14 May 2021, Ginkgo announced its new ticker for the NYSE will be "DNA". The ticker was previously used by Genentech, who stopped using the ticker after they were acquired by Roche. Trading began on September 17, 2021. The investment management firm Baillie Gifford became the largest shareholder (15%) with the purchase of 167.75 million shares on 31 March 2022.

On 14 March 2022, it was reported that Ginkgo Bioworks signed a Definitive Agreement to Acquire FGen AG, a leading bioengineering company and its proprietary ultra-high-throughput screening platform.

On 6 June 2022, it was reported that Ginkgo Bioworks has acquired assets from real-time metabolite monitoring company, Bitome.

On 25 July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300 million in an all-stock deal.

On 27 July 2022, it was reported that Ginkgo Bioworks would acquire Bayer's Biologics Research & Development site, located in West Sacramento. Ginkgo will enter into a new multi-year platform collaboration with Bayer. The deal includes the integration of the R&D platform assets from Joyn Bio, a joint-venture between Leaps by Bayer investments and Ginkgo Bioworks.

On 4 October 2022, it was reported that Ginkgo Bioworks would acquire France-based adaptive laboratory evolution instruments developer Altar and California-based Circularis to strengthen capabilities in cell and gene therapy.

In October 2022, Bloomberg News reported that Ginkgo Bioworks partnered with Intelligence Advanced Research Projects Activity to create a software tool to help detect when biological organisms have been genetically engineered. The tool known as ENDAR (short for Engineered Nucleotide Detection and Ranking) could be used to provide an early warning of bioweapons and other man-made biological threats.

Fraud allegations

On 6 October 2021, a market research firm published a report accusing Ginkgo of embellishing its revenue in a complex scheme highly dependent on related-party transactions. The report prompted an inquiry into Ginkgo by the United States Department of Justice. In November 2021, Ginkgo was sued in a shareholder lawsuit alleging it misrepresented its revenue sources in statements regarding its merger with a special-purpose acquisition company. As of 2021, the company could not name a single significant product that is manufactured and sold using its organisms.

In March 2023, the former Attorney General of Louisiana launched an investigation into the officers and directors of Ginkgo.

来源:维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗

Wikidata ↗

行业板块Healthcare 行业Life Sciences Tools & Services 员工485 国家US

10年表现 收入、净利润、利润率和每股收益趋势

06
收入$170M
2019-12-31 → 2025-12-31
EPS$-5.64
2019-12-31 → 2025-12-31
自由现金流$-179M
2022-12-31 → 2025-12-31
净利率-260.0%
2022-12-31 → 2025-12-31
估值与比率 07–12

估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜?

指标 5年趋势 DNA 5年均值 同行中位数 结论
P/E -2.35年均值 ≈-49.3 ≈-49.3 · ·
P/S (TTM) 7.05年均值 ≈202.7 ≈202.7 · ·
市净率 (MRQ) 1.95年均值 ≈49.7 ≈49.7 · ·
股价/自由现金流 (TTM) -4.55年均值 ≈-206.6 ≈-206.6 · ·
市现率 (TTM) -4.65年均值 ≈-242.4 ≈-242.4 · ·
市净率(有形资产) (MRQ) 2.15年均值 ≈115.0 ≈115.0 · ·

同行中位数按每项指标的标准化基础计算,可能与本股票显示的TTM/MRQ基础不完全匹配。

价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判

收益历史 每股收益实际值 vs 预估值,惊喜%,达标率,下次财报日期

14
平均惊喜 2.6%
期间报告EPS ActualEPS 预期惊喜
2026年6月30日 $-0.75 $-0.92 18.4%
2026年3月31日 $-1.39 $-1.09 -27.4%
2025年12月31日 $-1.41 $-1.47 4.1%
2025年9月30日 $-1.45 $-1.25 -15.8%
2025年6月30日 $-1.10 $-1.58 30.5%
2025年3月31日 $-1.68 $-1.79 6.0%

完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表

15
损益表 15
指标 趋势 2025202420232022202120202019
Revenue $170M$227M$251M$478M$314M$77M$54M
R&D Expense $244M$424M$581M$1.05B$1.15B$160M$96M
SG&A Expense $183M$246M$385M$1.43B$863M$38M$29M
Operating Expenses $485M$787M$1.12B$2.69B$2.14B$214M$126M
Operating Income $-315M$-560M$-864M$-2.21B$-1.83B$-137M$-72M
Interest Expense ··$93.0K$106.0K$2M$2M$2M
Other Non-op $2M$12M$-29M$88M$-10M$12M·
Pretax Income $-314M$-548M$-893M$-2.12B$-1.84B$-125M$-120M
Income Tax $-837.0K$-479.0K$-71.0K$-15M$-1M$2M$22.0K
Net Income $-313M$-547M$-893M$-2.10B$-1.83B$-127M$-119M
EPS (Basic) $-5.64$-10.54$-18.37$-50.15$-1.35$-0.10$-0.10
EPS (Diluted) $-5.64$-10.54$-18.37$-50.20$-1.39$-0.10$-0.10
Shares (Basic) 55,457,67651,894,63948,610,50741,976,5371,359,849,0001,274,766,9151,149,000,417
Shares (Diluted) 55,457,67651,894,63948,610,50741,995,9721,360,373,0001,274,766,9151,149,000,417
EBITDA $-315M$-560M$-864M$-2.21B···
资产负债表 28
指标 趋势 2025202420232022202120202019
Cash & Equivalents $167M$562M$944M$1.32B$1.55B$381M$495M
Short-term Investments $255M$0·····
Receivables $24M$22M$17M$81M$132M$17M·
Inventory ··$46.0K$4M$3M$3M·
Prepaid Expense $25M$19M$40M$52M$34M$21M·
Other Current Assets ··$362.0K$487.0K$698.0K$680.0K·
Current Assets $472M$603M$1.00B$1.45B$1.72B$427M·
PP&E (Net) $167M$204M$188M$315M$146M$121M·
PP&E (Gross) $355M$365M$309M$408M$207M$155M·
Accum. Depreciation $188M$161M$121M$93M$61M$34M·
Goodwill ·$0$49M$60M$21M$2M$2M
Intangibles $53M$73M$83M$111M$22M$3M·
Other Non-current Assets $9M$55M$58M$89M$44M$6M·
Total Assets $1.12B$1.38B$1.67B$2.54B$2.07B$675M·
Accounts Payable $11M$14M$9M$10M$8M$14M·
Accrued Liabilities ···$115M$93M$31M·
Short-term Debt ·····$300.0K·
Current Liabilities $96M$107M$164M$173M$135M$73M·
Capital Leases $417M$439M$222M$413M$0··
Other Non-current Liabilities $23M$17M$24M$31M$36M$3M·
Total Liabilities $611M$661M$568M$803M$504M$205M·
Common Stock $6.0K$5.0K$5.0K$190.0K$161.0K$129.0K·
Paid-in Capital $6.66B$6.56B$6.39B$6.14B$3.80B$929M·
Retained Earnings $-6.15B$-5.84B$-5.29B$-4.40B$-2.30B$-468M·
AOCI $2M$-2M$1M$-3M$-2M$0·
Stockholders' Equity $509M$716M$1.10B$1.74B$1.57B$470M·
Liabilities + Equity $1.12B$1.38B$1.67B$2.54B$2.07B$675M·
Shares Outstanding 58,207,29854,365,785,00050,032,87347,299,39940,284,8041,288,596,000·
现金流 16
指标 趋势 2025202420232022202120202019
D&A $59M$63M$71M$43M$29M$14M$11M
Stock-based Comp $82M$112M$230M$1.93B$1.61B$476.0K$771.0K
Deferred Tax $-1M$-936.0K$-801.0K$-15M$0$0·
Amort. of Intangibles $19M$18M$16M$6M$1M$500.0K$500.0K
Restructuring $11M$19M·····
Operating Cash Flow $-171M$-320M$-296M$-252M$-254M$-136M$-45M
CapEx $8M$63M$41M$52M$57M$58M$22M
Investing Cash Flow $-240M$-62M$-81M$-67M$-73M$-67M$-75M
Stock Issued $19M$0$0····
Stock Repurchased ······$408.0K
Net Stock Activity $19M······
Financing Cash Flow $18M$-2M$-3M$95M$1.53B$90M$410M
Net Change in Cash $-393M$-384M$-380M$-223M$1.21B$-113M$291M
Taxes Paid $192.0K$0$23.0K$981.0K$9M$0·
Free Cash Flow $-179M$-382M$-336M$-304M···
Levered FCF ··$-336M$-305M···
盈利能力 7
指标 趋势 2025202420232022202120202019
Operating Margin -185.3%-246.5%-343.8%-462.4%···
Net Margin -183.8%-240.9%-355.1%-440.6%···
Pretax Margin -184.3%-241.2%-355.1%-444.1%···
EBITDA Margin -185.3%-246.5%-343.8%-462.4%···
ROA -25.1%-36.0%-42.5%-91.3%···
ROE -55.8%-72.3%-76.0%-132.4%···
ROIC -61.8%-78.1%-78.8%-126.3%···
流动性与偿付能力 3
指标 趋势 2025202420232022202120202019
Current Ratio 4.95.66.18.4···
Quick Ratio 4.75.45.98.1···
Interest Coverage ··-9294.7-20839.2···
效率 2
指标 趋势 2025202420232022202120202019
Asset Turnover 0.10.10.10.2···
Receivables Turnover 7.411.65.14.5···
每股 5
指标 趋势 2025202420232022202120202019
Book Value / Share $8.74$13.17$0.55$0.92···
Revenue / Share $3.07$4.38$0.13$0.28···
Cash Flow / Share $-3.08$-6.16$-0.15$-0.15···
Cash / Share $2.87$10.33$0.47$0.70···
EPS (TTM) $-5.64$-10.54$-18.37$-50.20$-1.39··
增长率 3
指标 趋势 2025202420232022202120202019
Revenue YoY -25.1%-9.7%-47.4%52.2%309.4%··
Revenue CAGR 3Y -29.1%-10.2%48.6%····
Revenue CAGR 5Y 17.3%······
估值 (TTM) 10
指标 趋势 2025202420232022202120202019
Revenue TTM $170M$227M$251M$478M$314M··
Net Income TTM $-313M$-547M$-893M$-2.10B$-1.83B··
Market Cap $484M$534M$135.29B$127.90B···
P/E -1.5-0.9-3.7-1.3-239.1··
P/S 2.82.4538.0267.7···
P/B 1.00.7123.373.7···
P / Tangible Book 1.10.8140.281.7351.4··
P / Cash Flow -2.8-1.7-457.8-507.1···
P / FCF -2.7-1.4-402.3-420.1···
Earnings Yield -67.9%-107.3%-27.2%-74.3%-0.42%··

最近期在左侧 · 空值显示为 ·

财务报表 损益表、资产负债表、现金流量表 — 年度,近5年

16
指标 2025-12-312024-12-312023-12-312022-12-312021-12-31
收入 $170M $227M $251M $478M $314M
营业利润率 % -185.3% -246.5% -343.8% -462.4% ·
净收入 $-313M $-547M $-893M $-2.10B $-1.83B
稀释后每股收益 (EPS) $-5.64 $-10.54 $-18.37 $-50.20 $-1.39

机构持有人 (13F) 201 家申报者 · $379.7M 总计 · 截至 2026年6月30日

17

在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸;单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存,而非方向性判断。

持有人 201
持有价值 $379.7M
新仓位 31
已退出持仓 17
机构活动 — Q2 2026 与上一季度对比
新仓位 已退出持仓 增加 减少 净股数变动
31 (-1 与上一季度对比) 17 (-12 与上一季度对比) 71 (+18 与上一季度对比) 37 (-5 与上一季度对比) +4.5M

与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天,外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过,优先显示最近一个已完整报告的季度对。

机构 价值 股份 % 已追踪的13F 类型
BlackRock, Inc. $42443568 4282903 11.18% 股份
VIKING GLOBAL INVESTORS LP $35449338 3577128 9.33% 股份
Erste Asset Management GmbH $25902147 2536939 6.82% 股份
VANGUARD GROUP INC $24106911 2900952 6.35% 股份
BAILLIE GIFFORD & CO $23701242 2391649 6.24% 股份
VANGUARD CAPITAL MANAGEMENT LLC $20685074 2087293 5.45% 股份
Anchorage Capital Group, L.L.C. $17306457 1746363 4.56% 股份
Legal & General Group Plc $16543944 1669419 4.36% 股份
STATE STREET CORP $14591187 1472370 3.84% 股份
GEODE CAPITAL MANAGEMENT, LLC $12112753 1222016 3.19% 股份
VANGUARD PORTFOLIO MANAGEMENT LLC $9293628 937803 2.45% 股份
Allianz Asset Management GmbH $7787258 785798 2.05% 股份
UBS Group AG $6854341 691659 1.80% 股份
MILLENNIUM MANAGEMENT LLC $6329279 638676 1.67% 股份
AQR CAPITAL MANAGEMENT LLC $6160304 621625 1.62% 股份
SB INVESTMENT ADVISERS (UK) LTD $6052324 610729 1.59% 股份
GOLDMAN SACHS GROUP INC $6019096 607376 1.59% 股份
BANK OF AMERICA CORP /DE/ $5409393 545852 1.42% 股份
Prescott Group Capital Management, L.L.C. $5369684 541845 1.41% 股份
RENAISSANCE TECHNOLOGIES LLC $5349973 539856 1.41% 股份
SUSQUEHANNA INTERNATIONAL GROUP, LLP $4109677 414700 1.08% 买入期权
NORTHERN TRUST CORP $4014948 405141 1.06% 股份
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $3910555 394607 1.03% 股份
EXCHANGE TRADED CONCEPTS, LLC $3555540 358783 0.94% 股份
DIMENSIONAL FUND ADVISORS LP $3480392 351200 0.92% 股份
TUDOR INVESTMENT CORP ET AL $3326886 335710 0.88% 股份
VANGUARD FIDUCIARY TRUST CO $3097598 312573 0.82% 股份
Coastal Bridge Advisors, LLC $2743256 276817 0.72% 股份
Invesco Ltd. $2098175 211723 0.55% 股份
BALANCE CAPITAL PARTNERS L.P. $1972179 199009 0.52% 股份
ALGERT GLOBAL LLC $1784395 180060 0.47% 股份
Susquehanna Portfolio Strategies, LLC $1746449 176231 0.46% 股份
Bank of New York Mellon Corp $1689463 170481 0.44% 股份
BNP PARIBAS FINANCIAL MARKETS $1637935 165281 0.43% 股份
PEAK6 LLC $1619294 163400 0.43% 买入期权
CAXTON ASSOCIATES LLP $1532552 154647 0.40% 股份
D. E. Shaw & Co., Inc. $1499938 151356 0.39% 股份
Nuveen, LLC $1455234 146845 0.38% 股份
MORGAN STANLEY $1430152 144314 0.38% 股份
Universal- Beteiligungs- und Servicegesellschaft mbH $1387400 140000 0.37% 股份
JPMORGAN CHASE & CO $1368548 134040 0.36% 股份
CITADEL ADVISORS LLC $1297565 130935 0.34% 股份
SUSQUEHANNA INTERNATIONAL GROUP, LLP $1297219 130900 0.34% 卖出期权
a16z Capital Management, L.L.C. $1075909 108568 0.28% 股份
CITADEL ADVISORS LLC $1073253 108300 0.28% 买入期权
Numerai GP LLC $1036606 104602 0.27% 股份
AMERICAN CENTURY COMPANIES INC $974718 98357 0.26% 股份
WOLVERINE TRADING, LLC $964467 72900 0.25% 买入期权
Ensign Peak Advisors, Inc $931332 93979 0.25% 股份
PANAGORA ASSET MANAGEMENT INC $803592 81089 0.21% 股份

显示全部 201 个机构持有人 →

激进投资者及 5%+ 股东 4 持仓

18

提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权,意图影响发行人(激进股东持股、董事会活动、并购)。每一行显示该申报人持仓的最新已知状态。

申报人 已申报 持股 状态 目的 申报
Reshma P. Shetty, Barry Canton 2025年2月14日 9.50% 修订 · SEC
Jason Kelly ×4 申报 2024年2月14日 · 初始申报 · SEC
Reshma Shetty, Bartholomew Canton ×4 申报 2024年2月14日 · 初始申报 · SEC
VIKING GLOBAL INVESTORS LP, VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, O. ANDREAS HALVORSEN, DAVID C. OTT, ROSE S. SHABET ×3 申报 2022年3月4日 · 初始申报 · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

公司内部人士 17 位内幕人士 · 5 位高管 · 13 位董事

19
内部人士 角色 上次活动 持股数量 买入 12个月 卖出 12个月 净额 12个月
Jason R Kelly Chief Executive Officer & Founder 2026年7月28日 A 316483 0 2 $-1374823
Steven P. Coen Chief Financial Officer 2026年8月21日 M 51851 0 9 $-263897
Mark E. Dmytruk Chief Financial Officer 2025年5月20日 M 46226 0 0 $0
Reshma P. Shetty President & Founder 2026年7月28日 A 436422 0 3 $-977101
Marie E. Fallon Chief Accounting Officer 2023年5月1日 M 183010 0 0 $0
Christian O Henry 董事 2026年9月15日 S 19310 0 1 $-35400
Sri Kosuri 董事 2026年6月11日 A 24067 0 0 $0
Ross Fubini 董事 2026年6月11日 A 10822 0 0 $0
Harry Sloan 董事 2026年6月11日 A 271418 0 0 $0
Shyam Sankar 董事 2025年6月12日 A 72372 0 0 $0
Kathy Hopinkah Hannan 董事 2025年6月11日 M 15003 0 0 $0
Myrtle S Potter 董事 2025年6月11日 M 10822 0 0 $0
Arie Belldegrun 董事 2024年6月13日 A 194925 0 0 $0
Reshma Kewalramani 董事 2024年6月12日 M 186002 0 0 $0
Marijn E Dekkers 董事 2024年6月12日 M 386480 0 0 $0
Eagle Equity Partners III, LLC 董事 2021年9月16日 D 31590948 0 0 $0
Barry Canton 10% 所有者 2026年7月28日 A 436422 0 3 $-977101

来自SEC表格3/4/5申报的内部人士;净额=仅公开市场买卖

ETF持仓 由 25 只交易所交易基金持有

20

权重仅反映直接股权持仓(N-PORT);杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。

基金 权重 单位 截至 来源
THNQ · EXCHANGE TRADED CONCEPTS TRUST 0.69% 355179 NS 2026年7月31日 N-PORT
IDNA · iShares Trust 0.31% 115910 SH 2026年9月11日 每日
PRFZ · Invesco Exchange-Traded Fund Trust 0.08% 163763 SH 2026年10月2日 每日
IWC · iShares Trust 0.08% 160915 SH 2026年9月11日 每日
VTWV · VANGUARD SCOTTSDALE FUNDS 0.03% 41498 SH 2026年8月19日 每日
IBB · iShares Trust 0.02% 379730 SH 2026年9月11日 每日
RSSL · Global X Funds 0.01% 22732 NS 2026年7月31日 N-PORT
IWM · iShares Trust 0.01% 1228746 SH 2026年9月11日 每日
VXF · VANGUARD INDEX FUNDS 0.01% 549889 SH 2026年8月19日 每日
VTWO · VANGUARD SCOTTSDALE FUNDS 0.01% 274008 SH 2026年8月19日 每日
VHT · VANGUARD WORLD FUND 0.01% 112735 SH 2026年8月19日 每日
DFAS · Dimensional ETF Trust 0.00% 85360 NS 2026年7月31日 N-PORT
DXUV · Dimensional ETF Trust 0.00% 2967 NS 2026年7月31日 N-PORT
FHLC · FIDELITY COVINGTON TRUST 0.00% 17486 NS 2026年7月31日 N-PORT
DFSU · Dimensional ETF Trust 0.00% 4528 NS 2026年7月31日 N-PORT
VEGN · ETF Series Solutions 0.00% 324 NS 2026年7月31日 N-PORT
DCOR · Dimensional ETF Trust 0.00% 4838 NS 2026年7月31日 N-PORT
IWV · iShares Trust 0.00% 22370 SH 2026年9月3日 每日
ITOT · iShares Trust 0.00% 66426 SH 2026年9月11日 每日
DFAC · Dimensional ETF Trust 0.00% 29590 NS 2026年7月31日 N-PORT
DFAU · Dimensional ETF Trust 0.00% 5670 NS 2026年7月31日 N-PORT
DFUS · Dimensional ETF Trust 0.00% 10065 NS 2026年7月31日 N-PORT
VTI · VANGUARD INDEX FUNDS 0.00% 1489851 SH 2026年8月19日 每日
VTHR · VANGUARD SCOTTSDALE FUNDS 0.00% 3264 SH 2026年8月19日 每日
IWN · iShares Trust · 443818 SH 2026年9月11日 每日

DNA 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间

21
评级 · 10 位分析师 卖出
中位数目标 $7.00 -43.3%
0 0.0% 强烈买入
0 0.0% 买入
3 30.0% 持有
5 50.0% 卖出
2 20.0% 强烈卖出

12个月价格目标

2 位分析师 · 2026-10-03

平均目标 $7.00 -43.3%

高于所有目标 → 当前价格 $12.35
最低$5.00 平均值$7.00 最高$9.00

同行比较(GICS 子行业) 关键指标与行业同行对比

22

财年依据,价格截至各公司上一个财年末收盘价。

股票代码 市值 P/E 营收同比增长 净利润率 ROE 毛利率
DNA $484M -1.5 -25.1% -183.8% -55.8% ·
FTRE $1.61B -1.6 1.0% -36.2% -171.1% ·
BLFS · -241.8 28.9% · · ·
AZTA $1.32B -23.5 3.5% -9.4% -3.3% 45.5%
PSNL $816M -8.7 -17.7% -116.7% -36.0% ·
CYRX $479M 6.9 12.4% 44.4% 15.3% 47.1%
PACB $565M -1.0 3.9% -341.5% -1634.9% 28.6%
CTKB $649M 505.0 0.52% -33.0% -18.5% 51.8%
MLAB $489M 73.1 3.4% 2.7% 3.7% 63.5%
OABI · · · · · ·
TKNO $204M -11.9 7.3% -42.6% -23.8% 33.2%

最新新闻 提及该公司的近期头条新闻

23

我的指标 您的个人关注列表 — 来自完整基本面的选定行

26

选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。

您的选择已保存,并会跟随您浏览所有股票。

来源:SEC 10-Q 于 八月 6, 2026 申报